CN1822825A - 焦虑症的治疗 - Google Patents

焦虑症的治疗 Download PDF

Info

Publication number
CN1822825A
CN1822825A CNA01818927XA CN01818927A CN1822825A CN 1822825 A CN1822825 A CN 1822825A CN A01818927X A CNA01818927X A CN A01818927XA CN 01818927 A CN01818927 A CN 01818927A CN 1822825 A CN1822825 A CN 1822825A
Authority
CN
China
Prior art keywords
acid
treatment
dsm
purposes
nri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA01818927XA
Other languages
English (en)
Chinese (zh)
Inventor
H·R·托马森
D·米歇尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1822825A publication Critical patent/CN1822825A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA01818927XA 2000-11-15 2001-11-06 焦虑症的治疗 Pending CN1822825A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US26536201P 2001-01-31 2001-01-31
PCT/US2001/027801 WO2002040006A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Publications (1)

Publication Number Publication Date
CN1822825A true CN1822825A (zh) 2006-08-23

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA01818927XA Pending CN1822825A (zh) 2000-11-15 2001-11-06 焦虑症的治疗

Country Status (16)

Country Link
EP (1) EP1395253A2 (pt)
JP (1) JP2004529073A (pt)
KR (1) KR20030051812A (pt)
CN (1) CN1822825A (pt)
AU (1) AU2002217757A1 (pt)
BR (1) BR0115301A (pt)
CA (1) CA2426069A1 (pt)
CZ (1) CZ20031339A3 (pt)
EA (1) EA200300567A1 (pt)
HR (1) HRP20030384A2 (pt)
IL (1) IL155874A0 (pt)
MX (1) MXPA03004190A (pt)
NO (1) NO20032156D0 (pt)
PL (1) PL366119A1 (pt)
SK (1) SK5422003A3 (pt)
WO (1) WO2002040006A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113710319A (zh) * 2019-02-01 2021-11-26 霍夫曼技术有限责任公司 用于治疗焦虑相关病症的组合物和方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032380A3 (en) * 2001-03-06 2004-03-17 Eli Lilly And Company Inhibitor of monoamine uptake
CN1674907A (zh) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 瑞波西汀在治疗热潮红中的用途
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2009089479A2 (en) 2008-01-09 2009-07-16 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20120220665A1 (en) * 2009-11-03 2012-08-30 Mayo Foundation For Medical Education And Research Inhibiting Neurotransmitter Reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2931997A (en) * 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
ES2246485T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar la incontinencia.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113710319A (zh) * 2019-02-01 2021-11-26 霍夫曼技术有限责任公司 用于治疗焦虑相关病症的组合物和方法

Also Published As

Publication number Publication date
IL155874A0 (en) 2003-12-23
CZ20031339A3 (cs) 2003-10-15
NO20032156L (no) 2003-05-13
WO2002040006A3 (en) 2003-12-24
AU2002217757A1 (en) 2002-05-27
JP2004529073A (ja) 2004-09-24
MXPA03004190A (es) 2003-09-22
HRP20030384A2 (en) 2003-08-31
BR0115301A (pt) 2004-12-14
CA2426069A1 (en) 2002-05-23
WO2002040006A2 (en) 2002-05-23
EA200300567A1 (ru) 2004-10-28
EP1395253A2 (en) 2004-03-10
KR20030051812A (ko) 2003-06-25
NO20032156D0 (no) 2003-05-13
PL366119A1 (en) 2005-01-24
SK5422003A3 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
CN1146412C (zh) 去甲肾上腺素再摄取抑制剂在制备用于治疗对抗挑衅症的药物中的用途
EP3329909B1 (en) Fenfluramine for use in the treatment of dravet syndrome
Reimherr et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients
CN1271278A (zh) 行为障碍的治疗方法
KR20240011237A (ko) 우울증 치료를 위한 에스케타민
CN1207675A (zh) 丙炔苯丙胺的经颊和舌下给药法
CN1822825A (zh) 焦虑症的治疗
CN1889938A (zh) 用于预防或减少自杀性和治疗与自杀性相关的重性抑郁症的美金刚
DE60120109T2 (de) Verfahren zur herstellung von optisch reinem (r)- und (s)- didesmethylsibutramin
KR20020025252A (ko) 성기능 장애 치료를 위하여 효과발현이 신속한 선택적세로토닌 재흡수 억제제를 사용하는 방법
KR20090019765A (ko) 타액 분비 과다증 치료를 위한 알파-2 수용체 작용제(클로니딘) 및 항-무스카린제(옥시부티닌)의 복합물
US9314526B2 (en) Highly penetrating compositions with benzocaine for treating disordered tissues
Paap et al. Low-dose venlafaxine treatment in panic disorder
CN113710319A (zh) 用于治疗焦虑相关病症的组合物和方法
Borys et al. The effects of fluoxetine in the overdose patient
RU2560840C2 (ru) Способ лечения бессонницы
TW200300672A (en) Treatment of cognitive failure
Gómez‐Criado et al. Ziprasidone overdose: cases recorded in the database of Pfizer‐Spain and literature review
Horacek et al. The influence of clonidine on oral ketamine-midazolam premedication in intellectually disabled patients indicated for dental procedures: double-blind comparison of two sedation regimes
JP2005526695A (ja) シブトラミンおよびそれの代謝物の２−ヒドロキシ誘導体の製造方法および使用方法
Ashwath et al. Methadone-induced bradycardia
US20040034106A1 (en) Treatment of anxiety disorders
RU2477634C2 (ru) Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
JP5042425B2 (ja) 機能性胃腸疾患治療用トラマドール

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication